Hannah Clarke

"One of the notable things was the complications are frequent—which is something that was previously known about these surgeries—but they're minor," says Kayla Blickensderfer.

Projections were made under 3 different circumstances: the rate of women entering urology continues to follow logistic growth, there is no further growth of women into urology, and retirement rates among women mirror that of men in urology.

"Among our accomplishments were the first robotic ureteral reconstructions and completing our first 100 robotic cases within the first half-year," says Michael W. Witthaus, MD.

“This research shows the importance of diversity in clinical trials," said lead author Daniel J. George, MD.

“Both the SWOG S1011 and the LEA trial show very clearly that a bilateral standard node dissection confined to the true pelvis is the standard of care for patients with curable muscle-invasive bladder cancer," says Seth P. Lerner, MD, FACS.

A total of 398 patients with mCRPC, unselected for homologous recombination repair gene alterations.were included in the safety cohort.

“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.

"The pressures on physicians are making it extremely difficult to run a medical practice, and something needs to be done," says William C. Reha, MD, MBA.

"This is the first data to show that antegrade instillation of UGN-101 had lower ureteral stricture rates compared [with] retrograde approaches,” said Josh Gottlieb, DO.

"It's certainly a bigger problem with advancing age in the geriatric population, and it can be a tremendous source of cost for patients who have these issues," says Gina M. Rooker, MD.

Men of African ancestry were less likely to be treated on clinical trials after undergoing comprehensive genomic profiling compared with men of European ancestry.

The investigators found that patients who experienced recurrence following BCG therapy were more likely to have BRS3 tumors compared with BRS1 or BRS2.

"From a LUGPA vantage point, we are extremely excited to see the significant congressional attention to PBMs," says Mara R. Holton, MD.

The study assessed US veterans receiving care at the Veterans Health Administration for all cancer types, including prostate cancer.

Patients classified as GC high risk had a 5-year disease progression of 40%, compared with 20% among GC low-risk patients.

"We believe that more thorough body weight control in childhood could serve as a preventive measure for preserving testicular function in adulthood," says Rosella Cannarella, MD, PhD.

"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.

The trial assessed outcomes in patients who had kidney stones between 1 to 2 cm.

Trajectory inference analysis pointed to SIX2+CITED1+ as the nephrogenic cancer stem cells at the origin of Wilms tumor.

“These results validate the clinical value of bone biomarker assessment in the HSPC state," state the authors.

The findings held even when the investigators adjusted for age, past medical history, smoking status, and type of surgery.

The study also found a positive correlation between burnout and discrimination-based trauma in trainees.

In the study, 69% of patients who underwent complete ablation had no visible disease at first endoscopic evaluation, compared with 40% of patients who underwent chemoablation therapy.

Of all malignant bladder cancer lesions, 28% were only identified with blue light.

Patients who underwent sacrocolpopexy and were discharged on post-op day 0 had fewer instances of readmissions and fewer high-grade (class III-IV) complications.

"This institute model will lower barriers for access to some of the highest quality care in the world,” says Alexander Kutikov, MD, FACS.

"What was great about this partnership is we recognized that this is going to be the future of medicine at some point, and we want to be able to be a part of that cutting edge technology," says Nitin K. Yerram, MD.

Optimal bedtime was determined using the bedtime and mid-awake time for each patient, which was gathered from an Actiwatch Spectrum device.

In this installment, Suzanne B. Merrill, MD, FACS, and Dan Humer, PA-C, highlight Colorado Urology, a Denver-based practice within the United Urology group.

"In summary, it was safe and effective. There [were] no serious adverse events...and the vast majority of patients received no anesthesia with very similar results to shock wave lithotripsy,” said Ben H. Chew, MD, MSc, FRCSC.